$7,551.52 speaking Payment -- Johnson & Johnson to Dr. Steven Green

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

This payment of $7,551.52 from Johnson & Johnson to Dr. Steven Green, a dermatologist in Houston, TX, on October 9, 2025, was for his role as a speaker or faculty member. This type of payment, often related to educating peers about specific medications or treatments, is not uncommon in the pharmaceutical industry. The amount itself is substantial but falls within a range that can be seen for expert speakers in specialized medical fields. Johnson & Johnson is a major pharmaceutical company, and Dr. Green's specialty is dermatology. The payment is linked to Revlimid, a drug used to treat certain blood cancers and other conditions. When a physician receives compensation from a drug manufacturer, it's important to consider potential conflicts of interest. The Sunshine Act requires these payments to be publicly reported to promote transparency. While this payment doesn't automatically mean Dr. Green's medical decisions are compromised, it does create a relationship where he is being compensated by a company whose products he may prescribe. This compensation could potentially influence his views or recommendations, even unconsciously. Comparing this to industry averages is complex, as payment amounts vary widely based on the speaker's expertise, the topic, the duration of the engagement, and the specific drug or device being discussed. However, for a single speaking engagement, $7,551.52 is a significant sum. It's crucial for patients to understand that such relationships exist and to engage in open dialogue with their doctors about their treatment plans and any potential influences. The goal is to ensure that treatment decisions are always based on the patient's best interests and the latest medical evidence, not solely on industry-sponsored education.

Patient Guidance: What This Payment Means for You

It's understandable to feel concerned when you see payments between pharmaceutical companies and your doctor. This payment to Dr. Green from Johnson & Johnson was for speaking, likely educating other healthcare professionals about Revlimid. While this doesn't mean your care is compromised, it's a good opportunity to ensure transparency. At your next appointment, you can ask your doctor directly: 'I saw on the Open Payments database that you received a payment from Johnson & Johnson for speaking. Can you tell me more about that engagement and how it relates to my care?' This opens a dialogue. Remember, many doctors engage in these activities to share valuable information. The key is to ensure that prescribing decisions are always based on your individual needs, the best available evidence, and your doctor's objective medical judgment. If you have specific concerns about a medication or treatment, discuss them openly. Payments are routine for many specialists, but understanding the context is vital for your peace of mind and informed decision-making.

Payment Context: Is This Amount Normal?

Dermatologists, like many specialists, often receive payments from pharmaceutical companies for educational activities. Payments for speaking engagements can range from a few hundred to several thousand dollars, depending on the speaker's prominence and the nature of the engagement. While specific averages are hard to pinpoint for every single speaking event, this $7,551.52 payment is on the higher end for a single engagement, suggesting a potentially significant educational role. A notable percentage of dermatologists receive some form of payment from the industry.

Regulatory Context: Sunshine Act Requirements

The Sunshine Act, part of the Affordable Care Act, mandates that manufacturers of drugs, medical devices, and other healthcare items report payments and other transfers of value made to physicians and teaching hospitals. This specific payment, exceeding the $10 threshold, was required to be reported. Speaking engagements are a common category of reported payments. While not subject to special scrutiny beyond standard reporting, the public disclosure aims to increase transparency and allow patients to be informed about potential relationships.

Related Topics

This payment is related to the following healthcare transparency topics:

• pharma-payments
• dermatology
• sunshine-act
• speaker-fees
• johnson-and-johnson
• revlimid
• conflict-of-interest

Understanding speaking Payments

Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.

Frequently Asked Questions About This Payment

Does my doctor take pharma money?

You can check this yourself using the Centers for Medicare & Medicaid Services (CMS) Open Payments database online. Simply search for your doctor's name. The database lists payments made by pharmaceutical and medical device companies to physicians and teaching hospitals. Seeing a payment doesn't automatically mean your doctor is acting inappropriately; it simply means there's a financial relationship that is now publicly disclosed. It's a tool for transparency, allowing you to be more informed about your healthcare providers.

Should I worry about this payment?

This specific payment of $7,551.52 to Dr. Green from Johnson & Johnson for speaking is a significant amount, but it's important to view it in context. Payments for speaking engagements are common in many specialties. While it indicates a relationship, it doesn't automatically mean your care is compromised. Consider it an opportunity to have an open conversation with your doctor about their involvement and how it informs their practice. If your doctor is transparent and you trust their judgment, it may not be a cause for significant concern.

What types of pharma payments are most concerning?

Payments that might raise more concern are those that are less transparent or directly tied to prescribing specific products without clear educational value. This includes things like large consulting fees, excessive travel and dining expenses, or payments for research where the results might be influenced. While all reportable payments are disclosed, those that appear to be more like personal benefits or direct incentives for prescribing, rather than legitimate educational or research collaborations, warrant closer attention.

How do I talk to my doctor about pharma relationships?

Start by being direct and non-confrontational. You could say, 'I saw on the Open Payments website that you received a payment from [Company Name] for [Payment Type]. Could you tell me more about that?' Listen to their explanation. You can also ask, 'How do these relationships influence your prescribing decisions?' or 'Are there alternative treatments for my condition that aren't promoted by this company?' The goal is to foster open communication and ensure you feel confident in your treatment plan.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for doctors to accept payments from pharmaceutical and medical device companies, provided these payments are accurately reported under the Sunshine Act. The Act requires companies to disclose payments for things like speaking, consulting, research, meals, and travel. The legality hinges on transparency and adherence to reporting requirements. The payments themselves are not inherently illegal, but the intent and disclosure are key aspects regulated by the law.

Does pharma money affect what my doctor prescribes?

Research suggests that financial relationships with pharmaceutical companies can influence prescribing patterns, even if unconsciously. Doctors who receive payments may be more likely to prescribe the products of the companies that compensate them. However, this doesn't mean all doctors are unduly influenced. Many physicians maintain their objectivity. It's crucial to have open conversations with your doctor about treatment options and to seek second opinions if you have concerns about potential bias.

How does this compare to other doctors in this specialty?

Dermatology is a specialty where physicians often engage with pharmaceutical companies, particularly concerning new treatments and devices. Payments for speaking and consulting are relatively common. While $7,551.52 for a single speaking engagement is on the higher side, it's not an outlier compared to what some highly sought-after experts in the field might receive. Many dermatologists receive some form of payment, but the frequency and amount vary significantly across the profession.

Related Reports

• View Dr. Steven Green's full payment report
• Johnson & Johnson full spending report
• Browse all Dermatology payments
• Browse all payments in Texas
• Search for other payments